TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Diaceutics ( (GB:DXRX) ) just unveiled an announcement.
Diaceutics PLC has announced that Global Shares Trustees (UK) Limited and Zedra Trust Company (Guernsey) Limited have purchased ordinary shares on behalf of key personnel under the company’s Share Incentive Plan (SIP). The company has matched these purchases with a 1:1 share award, issuing 6,218 shares to the UK Trust. This move increases Diaceutics’ total shares in issue to 84,880,396, which may impact shareholder notifications under FCA rules.
The most recent analyst rating on (GB:DXRX) stock is a Buy with a £147.00 price target. To see the full list of analyst forecasts on Diaceutics stock, see the GB:DXRX Stock Forecast page.
Spark’s Take on GB:DXRX Stock
According to Spark, TipRanks’ AI Analyst, GB:DXRX is a Outperform.
Diaceutics’ strong technical momentum and positive corporate developments are offset by challenges in profitability and valuation concerns. The company’s strategic expansions and solid balance sheet provide a promising outlook, but immediate financial performance issues need addressing.
To see Spark’s full report on GB:DXRX stock, click here.
More about Diaceutics
Diaceutics PLC is a leading technology and solutions provider in the pharma and biotech industry. The company offers an end-to-end commercialization solution for precision medicines through data analytics, scientific and advisory services, facilitated by their platform DXRX – The Diagnostics Network.
Average Trading Volume: 161,880
Technical Sentiment Signal: Strong Buy
Current Market Cap: £116.2M
See more data about DXRX stock on TipRanks’ Stock Analysis page.